A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Phase 2 Completed 54 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).

Timeline

Start: 2020-09-14
Primary completion: 2023-08-29
Completion: 2024-02-13

Publications

Kennedy PTF, Fung S, Buti M, Yilmaz G, Chuang WL, Asselah T, Kurosaki M, Jezorwski J, Klyashtornyy V, Verbinnen T, Kakuda TN, Lenz O, Guinard-Azadian C, Biermer M. Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study. Gut. 2026 Apr 7;75(5):1043-1054. doi: 10.1136/gutjnl-2025-336592.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-73763989	Small interfering RNA (siRNA)	200 mg	Subcutaneous
Subject	PegIFN-alpha-2a	Protein / enzyme biologic	180 ug	Subcutaneous
Subject	bersacapavir	Other / unclassified	—	Oral
Background	Tenofovir disoproxil fumarate	Small molecule	—	Oral
Background	tenofovir alafenamide	Small molecule	—	Oral

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Summary

Timeline

Publications

Drugs

Indications